Braxia Scientific Corp. (BRAXF)
USD 0.0
(-9.09%)
USD 0.0
(-9.09%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.88 Million CAD | -66.62% |
| 2022 | 11.63 Million CAD | -37.08% |
| 2021 | 18.49 Million CAD | 1493.31% |
| 2020 | 1.16 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.7 Million CAD | -30.3% |
| 2024 Q3 | 2.33 Million CAD | -19.7% |
| 2024 Q2 | 2.91 Million CAD | 7.57% |
| 2023 Q4 | 3.88 Million CAD | -58.65% |
| 2023 FY | 3.88 Million CAD | -66.62% |
| 2023 Q3 | 9.39 Million CAD | -31.73% |
| 2023 Q2 | 13.76 Million CAD | 27.23% |
| 2023 Q1 | 10.81 Million CAD | -7.04% |
| 2022 Q4 | 11.63 Million CAD | -24.67% |
| 2022 FY | 11.63 Million CAD | -37.08% |
| 2022 Q3 | 15.44 Million CAD | -8.56% |
| 2022 Q2 | 16.89 Million CAD | -3.74% |
| 2022 Q1 | 17.54 Million CAD | -5.1% |
| 2021 Q1 | 22.48 Million CAD | 59.85% |
| 2021 Q3 | 20.09 Million CAD | -4.64% |
| 2021 Q2 | 21.07 Million CAD | -6.29% |
| 2021 FY | 18.49 Million CAD | 1493.31% |
| 2021 Q4 | 18.49 Million CAD | -7.99% |
| 2020 Q4 | 14.06 Million CAD | 1279.76% |
| 2020 Q3 | 1.01 Million CAD | 0.0% |
| 2020 FY | 1.16 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 90.002% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 46.202% |
| SQZ Biotechnologies Company | 107.18 Million USD | 96.376% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 63.198% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 97.017% |
| Mesoblast Limited | 667.9 Million USD | 99.418% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -5267.393% |
| Genus plc | 1.02 Billion USD | 99.622% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -185.943% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -678.319% |
| Marizyme, Inc. | 22.01 Million USD | 82.357% |
| ContraFect Corporation | 20.67 Million USD | 81.217% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -519.476% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -894.993% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -916.313% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -171.231% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 6.317% |
| MultiCell Technologies, Inc. | 126.22 USD | -3077157.17% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -313.34% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 96.978% |
| EV Biologics, Inc. | 431.71 Thousand USD | -799.696% |
| Q BioMed Inc. | 3.51 Million USD | -10.485% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 88.959% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -404.009% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1386.589% |
| Biomind Labs Inc. | 73.81 Thousand USD | -5161.672% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.161% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 87.059% |
| Skye Bioscience, Inc. | 11.94 Million USD | 67.471% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -17.238% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -41.429% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -98.352% |
| IMV Inc. | 31.33 Million USD | 87.604% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -464.974% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -49.206% |
| GB Sciences, Inc. | 103.44 Thousand USD | -3654.871% |
| Alpha Cognition Inc. | 2.45 Million USD | -58.395% |
| HST Global, Inc. | 1526.00 USD | -254429.096% |
| CSL Limited | 38.02 Billion USD | 99.99% |
| Halberd Corporation | 10.13 Thousand USD | -38238.9% |
| Enzolytics Inc. | 361.7 Million USD | 98.926% |
| Resverlogix Corp. | 8.11 Million USD | 52.137% |
| Affymax, Inc. | 7.44 Million USD | 47.815% |
| SYBLEU INC | 330.46 Thousand USD | -1075.337% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -106.835% |
| argenx SE | 4.54 Billion USD | 99.914% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 86.1% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 91.858% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -16949.796% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 56.598% |
| AVAX Technologies, Inc. | 7.37 Million USD | 47.349% |
| Zenith Capital Corp. | 7410.00 USD | -52317.193% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.885% |
| Ember Therapeutics, Inc. | 184.00 USD | -2110831.522% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1106.974% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1386.094% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.13% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -168.084% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -28.397% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 92.63% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -318.564% |
| BioStem Technologies, Inc. | 14.56 Million USD | 73.324% |
| ONE Bio Corp. | 70.08 Million USD | 94.458% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -6703.016% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -168043.463% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -293.142% |
| Agentix Corp. | 261.39 Thousand USD | -1385.935% |
| LadRx Corporation | 2.3 Million USD | -68.298% |
| Cell Source, Inc. | 195.17 Thousand USD | -1890.108% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -708.253% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -998.396% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -998.396% |
| NovAccess Global Inc. | 62.24 Thousand USD | -6139.741% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -507.219% |
| Itoco Inc. | 1.4 Million USD | -177.422% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -3960.46% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -3564.258% |
| Kadimastem Ltd | 2.3 Million USD | -68.575% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -4986.982% |
| CytoDyn Inc. | 11.13 Million USD | 65.121% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -2616.696% |
| Mobile Lads Corp. | 52.00 USD | -7469350.0% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -21623.233% |
| Qrons Inc. | 420.00 USD | -924689.048% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -907.628% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -603.491% |
| Rebus Holdings, Inc. | 5000.00 USD | -77582.28% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -848.682% |
| International Stem Cell Corporation | 5.39 Million USD | 27.939% |
| Bioxytran, Inc. | 137.63 Thousand USD | -2721.978% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 74.109% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 76.572% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -4816.6% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -349.198% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 48.329% |
| Neutra Corp. | 2851.00 USD | -136136.899% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 88.014% |
| PureTech Health plc | 693.97 Million USD | 99.44% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 51.876% |
| IXICO plc | 15.84 Million USD | 75.485% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 53.102% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.241% |
| CSL Limited | 38.02 Billion USD | 99.99% |
| Cellectis S.A. | 333.99 Million USD | 98.837% |